Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of APR-246 in Combination With Azacitidine as Maintenance Therapy for TP53 Mutated AML or MDS Following Allogeneic Stem Cell Transplant

NCT03931291 is registered in ClinicalTrials.gov with Aprea Therapeutics as lead sponsor.

NCT NCT03931291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03931291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of APR-246 in Combination With Azacitidine as Maintenance Therapy for TP53 Mutated AML or MDS Following Allogeneic Stem Cell Transplant
Lead sponsor
Aprea Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
September 16, 2019
Completion date
January 14, 2022
Enrollment
33 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia or myelodysplastic syndromes